Centro de Química Estrutural, Institute of Molecular Sciences and Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade de Lisboa, Campo Grande, 1749-016 Lisbon, Portugal.
J Med Chem. 2024 Oct 10;67(19):16967-16990. doi: 10.1021/acs.jmedchem.4c01680. Epub 2024 Sep 30.
Innovative strategies for targeted anticancer therapies have gained significant momentum, with metal complexes emerging as tunable catalysts for more effective and safer treatments. Rational design and engineering of metal complexes enable the development of tailored molecular structures optimized for precision oncology. The strategic incorporation of metal complex catalysts within combinatorial therapies amplifies their anticancer properties. This perspective highlights the advancements in synthetic strategies and rational design since 2019, showing how tailored metal catalysts are optimized by designing structures to release or synthesize active drugs, leveraging the target-specific characteristics to develop more precise cancer therapies. This review explores metal-based catalysts, including those conjugated with biomolecules, nanostructures, and metal-organic frameworks (MOFs), highlighting their catalytic activity in biological environments and their / performance. To sum up, the potential of metal complexes as catalysts to reshape the landscape of anticancer therapies and foster novel avenues for therapeutic advancement is emphasized.
创新的靶向抗癌疗法策略取得了重大进展，金属配合物作为可调催化剂，为更有效和更安全的治疗方法提供了可能。金属配合物的合理设计和工程化使定制分子结构的发展成为可能，从而优化精准肿瘤学。在组合疗法中战略性地引入金属配合物催化剂可以增强其抗癌特性。本综述重点介绍了 2019 年以来合成策略和合理设计方面的进展，展示了如何通过设计结构来释放或合成活性药物来优化靶向金属催化剂，利用靶向特性开发更精确的癌症疗法。本综述探讨了金属基催化剂，包括与生物分子、纳米结构和金属有机骨架（MOFs）结合的催化剂，强调了它们在生物环境中的催化活性及其性能。总之，强调了金属配合物作为催化剂在重塑癌症治疗领域和为治疗进展开辟新途径方面的潜力。
